{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:20:51Z","timestamp":1782307251615,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jaip.2023.04.029","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T17:58:42Z","timestamp":1683136722000},"page":"2150-2161.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2"],"prefix":"10.1016","volume":"11","author":[{"given":"Donna","family":"Carstens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego J.","family":"Maselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Genofre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2023.04.029_bib1","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2023.04.029_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00634-2017","article-title":"Severe eosinophilic asthma: a roadmap to consensus","volume":"49","author":"Buhl","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.04.029_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.04.029_bib4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1165\/ajrcmb.17.3.2733","article-title":"Eosinophil-associated TGF- \u03b21 mRNA expression and airways fibrosis in bronchial asthma","volume":"17","author":"Minshall","year":"1996","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaip.2023.04.029_bib5","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/cea.13465","article-title":"Blood eosinophil count correlates with severity of respiratory failure in life-threatening asthma and predicts risk of subsequent exacerbations","volume":"49","author":"Yii","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2023.04.029_bib6","article-title":"Blood eosinophil count and outcomes in severe uncontrolled asthma: a prospective study","volume":"5","author":"Zeiger","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.04.029_bib7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1513\/AnnalsATS.201310-354OC","article-title":"Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma","volume":"11","author":"Katz","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2023.04.029_bib8","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.jaip.2021.07.056","article-title":"Asthma phenotyping in primary care: applying the International Severe Asthma Registry eosinophil phenotype algorithm across all asthma severities","volume":"9","author":"Kerkhof","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.04.029_bib9","unstructured":"Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention (2021 Update). Accessed March 31, 2022. https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/05\/GINA-Main-Report-2021-V2-WMS.pdf"},{"key":"10.1016\/j.jaip.2023.04.029_bib10","unstructured":"US Food and Drug Administration. FDA Approves Fasenra (benralizumab) for Severe Eosinophilic Asthma. Accessed November 29, 2021. https:\/\/www.drugs.com\/newdrugs\/fda-approves-fasenra-benralizumab-severe-eosinophilic-asthma-4633.html"},{"key":"10.1016\/j.jaip.2023.04.029_bib11","series-title":"FASENRA (benralizumab) Prescribing information","year":"2021"},{"key":"10.1016\/j.jaip.2023.04.029_bib12","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.04.029_bib13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.029_bib14","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.04.029_bib15","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.04.029_bib16","first-page":"4381","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.029_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.12.049","article-title":"Elimination of oral corticosteroids (OCS) with benralizumab treatment in OCS-dependent asthmatics using a rapid, personalized algorithm: the PONENTE trial","volume":"147","author":"Menzies-Gow","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.029_bib18","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2023.04.029_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cea.14112","article-title":"Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis","volume":"52","author":"Charles","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2023.04.029_bib20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2023.04.029_bib21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4081\/mrm.2021.785","article-title":"Real world effectiveness of benralizumab on respiratory function and asthma control","volume":"16","author":"Menzella","year":"2021","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.jaip.2023.04.029_bib22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.anai.2022.02.017","article-title":"Real-world effectiveness of benralizumab: results from the ZEPHYR 1 Study","volume":"128","author":"Chung","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2023.04.029_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2023.04.029_bib24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1080\/03007995.2019.1595966","article-title":"Primary care of asthma: new options for severe eosinophilic asthma","volume":"35","author":"Skolnik","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2023.04.029_bib25","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jaip.2017.12.019","article-title":"Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma","volume":"6","author":"Ortega","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.04.029_bib26","series-title":"Improvement of clinical outcomes in severe eosinophilic asthma patients treated with benralizumab in real-world clinical practice in England: XALOC Study Programme","author":"Jackson","year":"2020"},{"key":"10.1016\/j.jaip.2023.04.029_bib27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s12890-021-01785-z","article-title":"Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)","volume":"21","author":"Mart\u00ednez-Morag\u00f3n","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2023.04.029_bib28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.18176\/jiaci.0599","article-title":"Benralizumab in real life","volume":"31","author":"Miralles L\u00f3pez","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.029_bib29","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1016\/j.chest.2020.05.007","article-title":"Real-life treatment of severe eosinophilic asthma with benralizumab","volume":"157","author":"Pelaia","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2023.04.029_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/JAA.S297273","article-title":"Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype expression","volume":"14","author":"Pelaia","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2023.04.029_bib31","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A study: Real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.04.029_bib32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, A Prospective Real-World Study","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.04.029_bib33","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1111\/all.14737","article-title":"Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma","volume":"76","author":"Kavanagh","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.04.029_bib34","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD effectiveness and safety of mepolizumab in a multicentric spanish cohort of asthma patients stratified by eosinophils: The REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jaip.2023.04.029_bib35","doi-asserted-by":"crossref","first-page":"107058","DOI":"10.1016\/j.rmed.2022.107058","article-title":"Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: A real-world Dutch cohort study","volume":"206","author":"Thelen","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2023.04.029_bib36","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/jcm8091375","article-title":"Severe eosinophilic asthma","volume":"8","author":"Bakakos","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaip.2023.04.029_bib37","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.04.029_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2017.12.001","article-title":"A retrospective cohort study in severe asthma describing commonly measured biomarkers: eosinophil count and IgE levels","volume":"134","author":"Haughney","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2023.04.029_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13223-020-00507-0","article-title":"Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts","volume":"17","author":"Ghassemian","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.029_bib40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.anai.2018.12.014","article-title":"Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab","volume":"122","author":"Kurosawa","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2023.04.029_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12890-020-01248-x","article-title":"Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study","volume":"20","author":"Numata","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2023.04.029_bib42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/JAA.S297273","article-title":"Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: Real-life evaluation correlated with allergic and non-allergic phenotype expression","volume":"14","author":"Pelaia","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2023.04.029_bib43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.04.029_bib44","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1080\/03007995.2017.1347091","article-title":"The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies","volume":"33","author":"Goldman","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2023.04.029_bib45","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2023.04.029_bib46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2147\/JAA.S295676","article-title":"Real-world experience with benralizumab in patients with severe eosinophilic asthma: a case series","volume":"14","author":"Menzella","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2023.04.029_bib47","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12890-020-01220-9","article-title":"Real-life experience with benralizumab during 6 months","volume":"20","author":"Padilla-Galo","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2023.04.029_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.631660","article-title":"Effectiveness of benralizumab in improving the quality of life of severe eosinophilic asthmatic patients: Our real-life experience","volume":"12","author":"Scioscia","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2023.04.029_bib49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: Data from the International Severe Asthma Registry and the US CHRONICLE study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2023.04.029_bib50","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jaip.2022.02.014","article-title":"Benralizumab effectiveness in severe asthma is independent of previous biologic use","volume":"10","author":"Jackson","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.04.029_bib58","unstructured":"Centers for Medicare & Medicaid Services. ICD-10. Modified December 1, 2021. Accessed January 1, 2022. https:\/\/www.cms.gov\/Medicare\/Coding\/ICD10\/"},{"key":"10.1016\/j.jaip.2023.04.029_bib59","unstructured":"ICD10Data.com. Accessed January 1, 2022. https:\/\/www.icd10data.com\/"},{"key":"10.1016\/j.jaip.2023.04.029_bib60","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2016.08.047","article-title":"Autoimmune diseases in adults with atopic dermatitis","volume":"76","author":"Andersen","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2023.04.029_bib61","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.jaip.2023.04.029_bib62","first-page":"848","article-title":"Economic burden of illness among patients with severe asthma in a managed care setting","volume":"22","author":"Chastek","year":"2016","journal-title":"J\u00a0Manag Care Spec Pharm"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823004701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823004701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T16:37:52Z","timestamp":1736872672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219823004701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2213219823004701"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2023.04.029","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2023.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}